SanBio Company Company Description

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States.

It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.

The company was founded in 2001 and is headquartered in Tokyo, Japan.

SanBio Company Limited

Country	Japan
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	33
CEO	Keita Mori

Contact Details

Address: St. Luke Tower Tokyo, 104-0044 Japan
Phone	81 3 6264 3481
Website	sanbio.com

Stock Details

Ticker Symbol	4592
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	February - January
Reporting Currency	JPY
ISIN Number	JP3336750009
SIC Code	2836

Key Executives

Name	Position
Keita Mori	Chief Executive Officer